Combination Studies with Gemcitabine in Non-Small-Cell Lung Cancer
Author Information
Author(s): WP Steward
Primary Institution: University Department of Oncology, Leicester Royal Infirmary
Hypothesis
Gemcitabine can be effectively combined with other agents to improve treatment outcomes in non-small-cell lung cancer.
Conclusion
Gemcitabine combined with cisplatin shows promising response rates and manageable toxicity in treating non-small-cell lung cancer.
Supporting Evidence
- Response rates for gemcitabine and cisplatin combinations ranged from 32% to 54%.
- The median survival for patients treated with gemcitabine and cisplatin was between 8.4 and 14.3 months.
- Neutropenia and thrombocytopenia were the most common side effects, but they were manageable.
Takeaway
Gemcitabine is a medicine that helps treat lung cancer, and when used with another medicine called cisplatin, it can help more people get better.
Methodology
Phase II studies evaluated the effectiveness and safety of gemcitabine in combination with cisplatin in patients with non-small-cell lung cancer.
Limitations
The studies had varying patient demographics and treatment schedules, which may affect the generalizability of the results.
Participant Demographics
Patients were primarily elderly, with a median age around 59-64 years, and included those with advanced stages of non-small-cell lung cancer.
Want to read the original?
Access the complete publication on the publisher's website